SPY323.50+0.86 0.27%
DIA268.10+0.52 0.19%
IXIC10,672.27+39.28 0.37%

Alimera Sciences Announces National Reimbursement Granted For ILUVIEN In The Netherlands

ILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously ATLANTA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM)

 · 

ILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously

ATLANTA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary received an add-on status for the pricing and reimbursement approval for ILUVIEN® in the Netherlands from the Ministry of Health, effective September 1, 2020. Pricing and reimbursement approval was sought and secured by Alimera’s distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is in the process of reviewing launch plans.

“We are extremely pleased to have received this national coverage decision for ILUVIEN’s diabetic macular edema and non-infectious posterior uveitis indications in the Netherlands at the same time,” said Rick Eiswirth, President and Chief Executive Officer of Alimera. “Given Horus’s impressive performance on the launch of ILUVIEN in France, we look forward to expanding distribution and sales in the Benelux region, and continuing to execute on our international growth strategy.”

ILUVIEN is a sustained release intravitreal implant indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU).

“We are genuinely pleased that for the second time, our collaboration with Alimera Sciences regarding ILUVIEN in Europe, has been fruitful,” said Maja Lausevic, Chief Operating Officer, Horus Pharma. “Access to ILUVIEN therapy is widely anticipated by ophthalmologists and patients in the Netherlands, and we are enthusiastic to provide this unique therapeutic solution to them and look forward to the official launch.”